Immunohistochemistry (IHC) detection of tumor PD-L1 expression, tumor mutational burden (TMB) and microsatellite instability (MSI) are the most commonly used biomarkers for predicting immune therapy response (67–69). Here, CD274 is linked to neoplasm.